User Conference
OPTIMIZE™ 24
Register today for the premier global event (April 29–May 3 in Houston, TX) for AspenTech customers, including users, operational leaders and executives within asset-intensive industries who are looking to elevate their business performance, improve their resiliency and meet their sustainability targets.
Brochure
Manufacturing Execution Systems (MES) for Pharma
Companies on their Pharma 4.0 journey need tools that foster compliance and are compatible with their existing hardware and digital ecosystem, so they can manage today’s dynamic environment. AspenTech’s flexible Manufacturing Execution Systems (MES) solution automates, guides and digitally records SOPs according to cGMP guidelines, reducing human error and minimizing risk of deviations.
Blog
New Paradigms of Sustainable Value in 2021
Sustainability has already started to drive investment in digitalization initiatives to support the need to accelerate innovation and change. The pace of investment will pick up in 2021.
Case Study
GlaxoSmithKline Speeds Up Batch Release Time: A Study in Digital Transformation
GSK wanted to review the structure of its batch production record and associated workflows as part of a continuous improvement process. AspenTech was selected for this process due to integration with other solutions, such as Aspen InfoPlus.21® and GSK’s existing plant automation software (DCS). The pilot project was a resounding success, reducing order preparation time by 95% and record review time by over 50%. Read this case study to learn more.
Video
Accelerate Your Pharma 4.0 Journey with Our Manufacturing Execution Systems (MES) Solution
Today’s pharmaceutical manufacturers face increasing pressure to deliver high-quality medicines quickly, efficiently and economically while complying with regulatory requirements and meeting sustainability goals. AspenTech’s Manufacturing Execution Systems (MES) solution digitally guides and records batch procedures in line with the ISPE’s Pharma 4.0 initiative, increasing production quality and reducing cycle time, cost and waste.
On-Demand Webinar
How GSK Reduces Errors and Improves Manufacturing Execution with Digitalization
Speed to market remains a key driver for the digitalization of long-standing paper-based processes in drug manufacturing. Bottlenecks such as manual execution and review—all associated with bloated documentation—prevent companies from aligning with the FDA’s vision for advanced manufacturing to achieve continuous improvement. Manufacturers like GlaxoSmithKline (GSK) are embracing Pharma 4.0 and paperless technologies to help bring quality medicines to patients more quickly.
Page 1 of 6